Aktis Oncology

The company is pre-revenue aside from collaboration revenue recognized over time from Lilly, and both lead assets are in Phase 1b. Management guides first dose-escalation readout for AKY-1189 in the first quarter of 2027, and AKY-2519 Phase 1b trials are enrolling across mCRPC and other B7-H3 tumors.

Until human efficacy signals and dose are established, revenue, FCF, and timelines remain inherently uncertain. Sector competition and isotope supply logistics add variability. Predictability improves materially only after proof of concept and expansion data.